“Significant Activity” for ADC in Ovarian Cancer

Mirvetuximab soravtansine plus bevacizumab may benefit women with recurrent ovarian cancer and high folate receptor alpha (FRα) expression, regardless of platinum sensitivity. In a phase I/II trial, the combination elicited an objective response rate of 64% and a median progression-free survival of 10.6 months in patients with FRα-high tumors.